Phosphorylated oligomannosidic or hybrid-type oligosaccharides present in recombinant therapeutic glycoproteins (CHO, BHK and HEK cells) may target the drug to undesired cells or tissues when applied in patients. In order to avoid these risks, cells culture supernatant as well as drug substance should be controlled for the absence of this type of oligosaccharides. TheraProteins is worldwide the only company that offers a panel of this type of structures valuable in N-glycosylation mapping analysis of biopharmaceutical proteins at any stage of development. | |